首页> 外文期刊>BMC Cancer >Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis
【24h】

Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis

机译:微染色体维持蛋白2的表达作为弥漫性大B细胞淋巴瘤增殖和预后的标志物:组织芯片和临床病理分析

获取原文
       

摘要

Background Minichromosome maintenance (MCM) proteins are essential for the initiation of DNA replication and have been found to be relevant markers for prognosis in a variety of tumours. The aim of this study was to assess the proliferative activity of diffuse large B-cell lymphoma (DLBCL) in tissue microarray (TMA) using one of the minichromosome maintenance proteins (Mcm2) and to explore its potential value to predict prognosis. Methods Immunohistochemistry for Mcm2 was performed on TMAs constructed from 302 cases of DLBCL. A monoclonal mouse antibody was used after heat induced antigen retrieval. Mcm2 expression was scored quantitatively. Positivity for Mcm2 was defined as presence of nuclear expression of Mcm2 in greater than or equal to 40 % of tumour cells. A statistical analysis was carried out of the association of Mcm2 and the clinico-pathological characteristics. Results Mcm2 expression was clearly evident in the nuclei of proliferating non-neoplastic cells and tumour cells. Positivity for Mcm2 was found in 46% (98/211) of analysable cases. A significant correlation existed between Mcm2 expression and presence of bulky disease (p = 0.003). Poor disease specific survival was observed in patients with DLBCL positive for Mcm2 expression in the univariate analysis (p = 0.0424). Conclusion Mcm2 expression can be used to assess tumour proliferation and may be useful as an additional prognostic marker to refine the prediction of outcome in DLBCL.
机译:背景技术微型染色体维持(MCM)蛋白对于DNA复制的启动至关重要,并且已被发现是多种肿瘤预后的相关标志物。本研究的目的是使用一种微染色体维持蛋白(Mcm2)评估组织芯片(TMA)中弥漫性大B细胞淋巴瘤(DLBCL)的增殖活性,并探讨其潜在价值以预测预后。方法对302例DLBCL患者的TMA进行Mcm2免疫组织化学分析。在热诱导抗原回收后使用单克隆小鼠抗体。对Mcm2表达进行定量评分。 Mcm2的阳性定义为在大于或等于40%的肿瘤细胞中存在Mcm2的核表达。对Mcm2与临床病理特征的关联进行了统计分析。结果Mcm2表达在增殖的非肿瘤细胞和肿瘤细胞的核中明显可见。在46%(98/211)的可分析病例中发现了Mcm2的正值。 Mcm2表达与大块疾病的存在之间存在显着相关性(p = 0.003)。在单变量分析中,在Mcm2表达阳性的DLBCL患者中观察到疾病特异性生存率较差(p = 0.0424)。结论Mcm2表达可用于评估肿瘤的增殖,并可作为补充预后的指标,以改善DLBCL的预后。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号